scispace - formally typeset
L

Louisa Kalsner

Researcher at University of Connecticut

Publications -  13
Citations -  316

Louisa Kalsner is an academic researcher from University of Connecticut. The author has contributed to research in topics: Exome sequencing & Exome. The author has an hindex of 7, co-authored 11 publications receiving 202 citations. Previous affiliations of Louisa Kalsner include University of Connecticut Health Center.

Papers
More filters
Journal ArticleDOI

Prader-Willi, Angelman, and 15q11-q13 Duplication Syndromes.

TL;DR: The clinical background, genetic cause, diagnostic strategy, and management of each of these three distinct neurodevelopmental disorders arise primarily from deletions or duplications that occur at the 15q11-q13 locus are discussed.
Journal ArticleDOI

Natural history and genotype-phenotype correlations in 72 individuals with SATB2-associated syndrome.

Yuri A. Zarate, +58 more
TL;DR: It is confirmed that the most distinctive features are neurodevelopmental delay with invariably severely limited speech, abnormalities of the palate (cleft or high‐arched), dental anomalies (crowding, macrodontia, abnormal shape), and behavioral issues with or without bone or brain anomalies.
Journal ArticleDOI

SPEN haploinsufficiency causes a neurodevelopmental disorder overlapping proximal 1p36 deletion syndrome with an episignature of X chromosomes in females

Francesca Clementina Radio, +117 more
TL;DR: In this article, the authors used clinical data from 34 individuals with truncating variants in SPEN to define a neurodevelopmental disorder presenting with features that overlap considerably with those of proximal del1p36 syndrome.
Journal ArticleDOI

Genetic testing including targeted gene panel in a diverse clinical population of children with autism spectrum disorder: Findings and implications.

TL;DR: Genetic testing of children with autism spectrum disorder is now standard in the clinical setting, with American College of Medical Genetics and Genomics guidelines recommending microarray for all children, fragile X testing for boys and additional gene sequencing, including PTEN and MECP2, in appropriate patients.